Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3785/j.issn.1008-9292.2020.03.01 http://scihub22266oqcxt.onion/10.3785/j.issn.1008-9292.2020.03.01 32391659!8800720!32391659     free     free     free Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538       Zhejiang+Da+Xue+Xue+Bao+Yi+Xue+Ban 2020 ; 49 (2): 158-169 Nephropedia Template TP {{tp|p=32391659|t=2020. Pharmaceutical care for severe and critically ill patients with COVID-19 |pdf=|usr=}}{{32391659}} gab.com Text Pharmaceutical care for severe and critically ill patients with COVID-19 JO: Zhejiang Da Xue Xue Bao Yi Xue Ban http://www.kidney.de/pget.php?&tw=1&pmid=32391659 #FOAvip Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients. Twit Text FOAVip Pharmaceutical care for severe and critically ill patients with COVID-19 ????Zhejiang Da Xue Xue Bao Yi Xue Ban http://www.kidney.de/pget.php?&tw=1&pmid=32391659 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32391659 #FOAvip English Wikipedia <ref>{{Cite pmid|32391659}}</ref> Pharmaceutical care for severe and critically ill patients with COVID-19 #MMPMID32391659 Jiang S; Li L; Ru R; Zhang C; Rao Y; Lin B; Wang R; Chen N; Wang X; Cai H; Sheng J; Zhou J; Lu X; Qiu Y Zhejiang Da Xue Xue Bao Yi Xue Ban 2020[May]; 49 (2): 158-169 PMID32391659show ga Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients. |*Coronavirus Infections/drug therapy[MESH] |*Drug Therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy[MESH] |Adrenal Cortex Hormones/adverse effects/therapeutic use[MESH] |Anti-Bacterial Agents/therapeutic use[MESH] |Antiviral Agents/adverse effects/therapeutic use[MESH] |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |Critical Illness[MESH] |Humans[MESH] |Nutritional Support[MESH] |Probiotics/administration & dosage[MESH] Pharmaceutical care for severe and critically ill patients with COVID(epmc).pdf DeepDyve Pubget Overpricing